Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, May 16, 2016
U.S. FDA Approves Additional Indication for Eisai's Anticancer Agent Lenvima in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma
Thursday, April 14, 2016
Aricept Approved in the Philippines for New Indication as Treatment for Dementia with Lewy Bodies
Tuesday, April 5, 2016
Eisai Receives Positive CHMP Opinion on New Indicator for Anticancer Agent Halaven for Treatment of Advanced Liposarcoma
Thursday, March 31, 2016
Eisai Transfer the Rights to Investigational Anticancer Agent E7777 for European, U.S and Certain Emerging Markets to Dr. Reddy's Laboratories
Wednesday, March 30, 2016
Eisai Co., Ltd. and Ajinomoto Co., Inc. Announce Establishment of Gastrointestinal Specialty Pharma EA Pharma Co., Ltd.
Eisai's Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2016
Eisai's Notice Concerning Shelf Registration for Issuance of Stock Options
Tuesday, March 29, 2016
Eisai's In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) Approved in Japan
Tuesday, March 22, 2016
Eisai Withdraws New Drugs Application for Mecobalamin Ultra-High Dose Preparation as Treatment for Amyotrophic Lateral Sclerosis
Thursday, March 17, 2016
Notice Regarding Discontinuation of Sales and Voluntary Recall of Egg White Lysozyme Preparation Neuzym

Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: